Bantam Pharmaceutical Board


Michael Luther, PhD, MBA

28+ years executive experience in successfully leading drug discovery & development companies from start ups to global pharma including GSK and Merck. Part of 4 launched product teams as well as multiple compounds from bench to clinical development.

Strong operations and business development experience including leading $100 million P/Ls.

Victor F. Keen

Practicing attorney 40+ years, currently Of Counsel at Duane Morris

CEO 3DIcon Corp (OTCQB: TDCP) since 2012

Former Board Member Research Frontiers (NASDAQ: REFR)

Lionel Goldfrank III

Principal in several private investment companies.

Founder of American & Overseas Asset Services Corporation.

Formerly with Goldman Sachs & Company.

W. James Tozer, Jr.

Co-owner and Founder of Vectra Management Group, real estate investment firm.

Formerly with Citibank, Shearson Hayden Stone, Marine Midland & Prudential-Bache Securities.

Founding investor in LendingTree, Vectra Bank Colorado & Draper Bank.

Active Director in Pharma & medical device companies GangaGen, PhotoPharmics & PenBlade.

Bantam Pharmaceutical Management


Michael Luther, PhD, MBA President & Chief Executive Officer

28+ years executive experience in successfully leading drug discovery & development companies from start ups to global pharma including GSK and Merck. Part of 4 launched product teams as well as multiple compounds from bench to clinical development.

Strong operations and business development experience including leading $100 million P/Ls.

Jedd Levine, MD, MBA Chief Medical Officer

Medical oncologist. Experience includes Oncology Divisions at Stanford, Yale, and as Managing Partner at Connecticut Oncology and Hematology.

Chief Medical Officer, Oncoplex Diagnostics.

Matthew Kostura, PhD Chief Scientific Officer

25+ years of experience in drug discovery & development including roles at Merck, GSK and TransTech Pharma in areas of oncology, inflammation, and metabolic disease. Led 4 successful FTIH project teams

Expert in high-content, multi-modal, phenotypic profiling

Vibha Oza, PhD Chief Operating Officer

15+ years of oncology drug discovery & development with AstraZeneca and Vertex

Extensive experience in leading Lead to IND programs and ventures

Seasoned Medicinal Chemist with experience in kinases, PPIs and GPCRs

Alan Cooper, PhD Head of Chemistry

Medicinal chemist with over 38 years of experience leading drug discovery and early stage clinical trials at Schering-Plough and Merck.

Led multiple project teams including marketed and current compounds in development.

Over 100 publications/patents and expertise in oncology, anti-infectives, and immunology drug discovery.

Meghan Reynolds Administrative Manager

Decade of administrative experience in the fields of asset management and biotechnology

Roles in investor relations, corporate restructuring/asset sale, and start up management

Bantam Scientific Advisory Board


Briggs Morrison, MD, PhD Chair of Scientific Advisory Board

Former Chief Medical Officer, Pfizer and Astra Zeneca

Managing Partner, MPM Capital

CEO Syndax Pharmaceuticals

Michael Patane, PhD Scientific Advisor

Former Exec. Director of Chemistry, Merck; and Millennium

Chief Scientific Officer, MitoBridge Pharmaceuticals

Rainer Fuchs, PhD Scientific Advisor

Former Vice President and Head of Biogen Innovation Incubator

Chief Information Officer, Harvard Medical School

Nahum Sonenberg, PhD Scientific Advisor

Professor, Dept. of Biochemistry and Goodman Cancer Research Centre, McGill University

Leading authority on mRNA translation and eIF4E

Adrian Schwarzer, MD, PhD Scientific Advisor

Institute of Experimental Hematology, Hannover Medical School

Gerald Shipps, PhD Scientific Advisor

Former Directory of Chemical Research, Merck and Schering-Plough

Executive Director, Shire Pharmaceuticals

Interested in contacting Bantam regarding further information?